XORTX Therapeutics, Inc. · TSXV:XRTX

XORTX Therapeutics — Investor Presentation (October 2026)

21 slides from XORTX Therapeutics's investor presentation, October 2026

  1. Slide 1: Xanthine Oxidase Reducing Technology

    Xanthine Oxidase Reducing Technology Targeting Gout and Progressive Kidney Disease October 2026 : ANUA

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain information included in this Presentation constitutes “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws (“forward-looking statements”). These statements relate to future events or future performance of XO

  3. Slide 3: Investment Highlights

    Investment Highlights SHORT XRx-026 for gout targeted for NDA approval by H1 2028 TIMELINE G O LIMITED Safe and effective clinical record in over 850 patients U RISK T LARGE >$0.5B* peak sales opportunity created by decline of a marketed MARKET allopurinol alternative after receiving a Black Box War

  4. Slide 4: Gout Overview

    Gout Overview Common Symptoms of Gout Caused by a Build-Up of Uric Acid crystals in tissues Causes Severe Pain and Discomfort - particularly joints, classic ‘big toe pain’ Multiple associated-disease conditions Pain in wrist Prevalence has doubled in the last 20 years and predicted to double in next

  5. Slide 5: Gout - Estimated Addressable U.S. Market

    Gout - Estimated Addressable U.S. Market 47 People with elevated Uric Acid Million levels 7 Million Patients diagnosed with gout $0.5 – 1.0 Billion 280,000 Allopurinol-intolerant gout patients Targeted peak sales of XRx-026, XORTX’s gout drug Projected annual drug price per $6-8,000 patient Febuxost

  6. Slide 6: Market Opportunity: Febuxostat

    Market Opportunity: Febuxostat ‘GAP’ * N/A* N/A* N/A* N/A* • 2008 - Febuxostat entered the US gout market targeting allopurinol intolerance (~3-5% of patients) • 2019 - Received a black box warning; prescriptions dropped • 2024 – Febuxostat sales were less than $30M 2026 - No drug currently fills th

  7. Slide 7: Oxypurinol Safety in Allopurinol Intolerant Patients

    Oxypurinol Safety in Allopurinol Intolerant Patients • Over 850 allopurinol-intolerant patients have been successfully treated with oxypurinol. • Oxypurinol has been proven safe and effective in typical gout and in allopurinol-intolerant gout patients. • Oxypurinol offers gout patients who don’t res

  8. Slide 8: Gout - Competitive Landscape

    Gout - Competitive Landscape DRUG STATUS XRx-026 (xanthine oxidase inhibitor) PRE-NDA READY XORTX Therapeutics Inc. Allopurinol (xanthine oxidase inhibitor) FDA APPROVED Generic FDA APPROVED Febuxostat (Black Box Warning (xanthine oxidase inhibitor) – acute cardiac Takeda, various generics death and

  9. Slide 9: Gout (XRx-026): Regulatory and Clinical Development Plan

    Gout (XRx-026): Regulatory and Clinical Development Plan* 2026 2027 2028 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Type “B” IND Filing Marketing REGULATORY Meeting NDA Filing NDA Review CTA Filing / Revenue PK Study (XRX-OXY-102) CLINICAL CTA Part 1 : IND Part 2 DS & DP Validation and PRODUCT Commercial B

  10. Slide 10: Proprietary Oxypurinol Formulation for Gout

    Proprietary Oxypurinol Formulation for Gout Formulation enables maximum drug Oxypurinol - the most uptake. Pipeline-in-a-product effective Uric Acid patented technology Lowering Agent available Proprietary and highly scalable CMC approach; Once daily oral dosing IP Formulated to Optimize Absorption

  11. Slide 11: Pipeline - ADPKD Overview

    Pipeline - ADPKD Overview Common Symptoms of ADPKD Causes liver cysts, pain and discomfort Leads to decreased kidney function and ultimately to end-stage kidney disease Associated with increased incidence of neurologic aneurisms, cardiovascular disease 160,000 patients in the US - Treatments are lim

  12. Slide 12: ADPKD - Estimated Addressable U.S. Market

    ADPKD - Estimated Addressable U.S. Market U.S. Population ~337,000,000 U.S. ADPKD Population Diagnosed ~160,000 % of ADPKD Population Stage 2, 3, 4 ~96,000 % of ADPKD with Cost of Dialysis/yr hyperuricemia ~$90,000 ~38% (~36,500) Estimate U.S. Cost of Tolvaptan/yr Peak Sales Future net sales revenue

  13. Slide 13: Pipeline - VB4-P5 Overview

    Pipeline - VB4-P5 Overview Renal Fibrosis Chronic kidney disease (CKD) affects an estimated 14% (1 in 7) of adults globally, ~ 35–37 million Renal fibrosis is strongly linked to chronic kidney disease (CKD), individuals in the United States. which affects an estimated 35.5 million American adults. R

  14. Slide 14: Pipeline - VB4-P5 Overview cont…

    Pipeline - VB4-P5 Overview cont… Etiology of Renal Fibrosis The excessive scarring and accumulation of extracellular matrix in the kidney The final common pathway of many chronic kidney diseases Leads to progressive loss of kidney function and eventual end-stage renal failure It is strongly linked t

  15. Slide 15: Milestones

    Milestones IND submission: gout – H4 2026 PK study results: gout – H2 2027 Completion of CM&C validation: gout – H2 2027 Stability studies initiated: gout – H1 2027 NDA submission: gout – H1/2 2027 15

  16. Slide 16: Kidney Disease Multi-Billion Dollar Acquisitions

    Kidney Disease Multi-Billion Dollar Acquisitions March 31, 2026 - Biogen Acquired Apellis Key Themes Pharmaceuticals (Nephrology) Transaction Value: Approximately $5.6 Billion + CVR • Kidney disease programs and their parent companies are increasingly attractive April 30, 2025 - Novartis Acquired Re

  17. Slide 17: Team - Management

    Team - Management Allen W. Davidoff, Ph.D., Co-Chief Executive Officer Dr. Davidoff has 20 years of drug development experience and is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D. Previously, Allen

  18. Slide 18: Board of Directors

    Board of Directors George Scorsis – Chairman George Scorsis is a results-focused executive with over 20 years of leadership experience in highly regulated sectors such as pharmaceuticals, and consumer-packaged goods. Exceptional at scaling businesses, optimizing operations, and managing complex envi

  19. Slide 19: XORTX Cap Table

    XORTX Cap Table Capitalization as of October 25, 2026 % of Fully # of Shares Diluted Common Shares Outstanding (Insiders): 25,290 0.5% Common Shares Outstanding (Other): 2,221,275 40.4% Total Common Shares Outstanding 2,246,565 40.9% Warrants Outstanding: 3,236,628 58.9% Options Outstanding: 16,541

  20. Slide 20: Summary

    Summary SHORT XRx-026 for gout targeted for NDA approval by H1 2028 TIMELINE G O LIMITED Safe and effective clinical record in over 850 patients U RISK T LARGE >$0.5B* peak sales opportunity created by a marketed MARKET allopurinol alternative receiving a Black Box Warning XRx-008 for ADPKD† to begi

  21. Slide 21: XORTX Therapeutics Inc. contact details

    XORTX Therapeutics Inc. 3710 33rd St NW Calgary, Alberta T2L 2M1 (403) 455-7727 info@xortx.com / www.xortx.com : ANUA 21

XORTX Therapeutics — Investor Presentation (October 2026) on 6ix